KROS
Keros Therapeutics, Inc.
There isn't enough reported data to score KROS yet.
UNH
UnitedHealth Group Incorporated
UNH's fundamentals are mixed: free cash flow grew 31%, but earnings per share fell 8.5%. At 23x earnings, it's trading right at its usual valuation. Analysts expect strong earnings growth, though they disagree widely on how much.
KROS Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Weak | |
| Strong |
KROS's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
KROS PE Valuation
KROS has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
KROS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong decline | |
| -- | |
| Limited | |
| High |
Analysts expect KROS's losses to grow, with revenue declining.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
KROS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.34 | -251% |
| Q2 2026 | -$3.22 | -1106% |
| Q1 2026 | -$2.53 | -$2.36 |
| Q4 2025 | $2.30 | +$7.30 |
| Q3 2025 | $1.55 | +$6.76 |
| Q2 2025 | $0.32 | +$5.45 |
| Q1 2025 | -$0.17 | +$4.98 |
| Q4 2024 | -$5.00 | +$0.20 |
KROS has swung to a loss: it lost $2.34 per share over the past year, after a profit the year before.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over KROS on earnings quality, reporting a profit while its opponent remains loss making.
KROS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $40M | +183% |
| Q1 2026 | $367K | -100% |
| Q4 2025 | $380K | -88% |
| Q3 2025 | $14.1M | +3540% |
| Q2 2025 | $18.2M | +49003% |
| Q1 2025 | $211.2M | +254348% |
| Q4 2024 | $3M | +2027% |
| Q3 2024 | $388K | +4750% |
KROS's revenue is recovering but still below its 2025 peak: $40M last quarter, up 183% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 32% | +141 points |
| Q1 2026 | -7051% | -7123 points |
| Q4 2025 | -7703% | -5952 points |
| Q3 2025 | -109% | +15009 points |
| Q2 2025 | -219% | +136103 points |
| Q1 2025 | 72% | +58485 points |
| Q4 2024 | -1751% | +30735 points |
| Q3 2024 | -15118% | +525882 points |
KROS has the edge over UNH on profitability, with a higher operating margin.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH's revenue has held roughly level: $113B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH's operating margin was 5.8% last quarter, up 2 points from the same quarter a year ago.
KROS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $3.3M | +6.9% |
| Q2 2026 | -$20.6M | +$9.8M |
| Q1 2026 | -$3.6M | -102% |
| Q4 2025 | -$27.4M | +$18.9M |
| Q3 2025 | $3.1M | +$34M |
| Q2 2025 | -$30.3M | +$9.8M |
| Q1 2025 | $160.6M | +$206.1M |
| Q4 2024 | -$46.3M | -$20.3M |
KROS has burned cash in almost every quarter: −$48M over the past year, against $87M the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over KROS on cash generation, producing positive trailing cash flow while its opponent burns cash.
KROS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.7% | +541K shares |
| 1 year | -50% | -20.3M shares |
| 3 years | -31% | -9.3M shares |
| 5 years | -13% | -3M shares |
| Available history | +129% | +11.5M shares |
KROS has the edge over UNH on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2019 | — |
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has 902M diluted shares, down 0.7% from a year ago, with $5B in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
KROS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2025 | -4.2x | Net Cash |
| Q3 2025 | -15.4x | Net Cash |
| Q2 2025 | -412.8x | Net Cash |
KROS has more cash than debt.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
KROS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.8 | Neutral |
| Stochastic | 29.8 | Neutral |
KROS's weekly RSI is 43 (neutral) and its Stochastic is 30 (neutral).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
KROS PE vs Healthcare Sector
| Metric | KROS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
KROS has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
KROS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $10.9 | 7.7% below |
| 20 week MA | $10.9 | 7.5% below |
| 50 week MA | $13.0 | 22% below |
| 100 week MA | $13.5 | 25% below |
| 200 week MA | $30.6 | 67% below |
KROS is in a downtrend: it's below all five of its weekly moving averages, and 67% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over KROS on trend strength, trading above more of its moving averages.
KROS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $21.6 | $78.5 | +264% |
| 2021 | $78.5 | $58.8 | -25% |
| 2022 | $58.8 | $46.7 | -21% |
| 2023 | $46.7 | $39.8 | -15% |
| 2024 | $39.8 | $16.4 | -59% |
| 2025 | $16.4 | $21.0 | +28% |
| 2026 YTD | $21.0 | $10.1 | -52% |
KROS's yearly returns have swung widely, from +264% in 2020 to −59% in 2024. It's down 52% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over KROS on returns for 2026, with the stronger performance.